We recently reported that 4 out of 6 patients with refractory schizophrenia improved with the cannabinoid agonist dronabinol (synthetic A'-tetrahydrocannabinol).1 We have subsequently tried dronabinol in a purely clinical manner for 8 other inpatients with refractory psychosis in our tertiary care hospital. Inclusion criteria were severe psychosis refractory to standard medication, a history of symptomatic improvement when using marijuana, and good physical health. We now report on the 4 patients who improved with dronabinol. The trials reported here occurred between November 2009 and April 2010. Dronabinol use was approved by the joint institutional review board of the Rockland Psychiatric Center and Nathan S. Kline Institute for Psychiatric Research (Orangeburg, New York) and given according to our hospitals formal protocol for administering US Food and Drug Administration-approved medication for off-label use.
展开▼
机译：我们最近报道说，使用大麻素激动剂Dronabinol（合成的A'-四氢大麻酚）改善了6例难治性精神分裂症患者中的4例。1随后，我们在三级医院中以纯临床方式对其他8例难治性精神病住院患者尝试了Dronabinol。入选标准为标准药物难以治疗的严重精神病，使用大麻时症状改善的历史以及身体健康。现在，我们报告了4例Dronabinol改善的患者。此处报道的试验发生在2009年11月至2010年4月之间。Dronabinol的使用得到Rockland精神病学中心和Nathan S. Kline精神病学研究所（纽约州奥兰治堡）的联合机构审查委员会的批准，并根据我们医院的正式方案进行用于管理美国食品药品监督管理局批准的非标签使用药物。
展开▼
